About Dr. Rachel Salzman
Dr. Rachel Salzman serves as Chief Executive Officer (CEO) at Armatus Bio, a privately held preclinical stage biotech focusing on curative approaches for neuromuscular disorders where toxic gain of function plays a causative role in disease pathology. Prior to joining Armatus, Rachel was Executive Vice President of Portfolio, External Affairs & Development at Alcyone Therapeutics, a precision medicines company advancing therapies in serious neurological disorders by integrating novel delivery technologies with innovative genetic platforms.
